查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1870479

犬类关节炎治疗市场依治疗方法、药物类别、给药途径、通路、最终用户和公司划分－2025-2032年全球预测

Canine Arthritis Market by Treatment Type, Drug Class, Route Of Administration, Distribution Channel, End User, Company - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，犬类关节炎治疗市场将成长至 36.7 亿美元，复合年增长率为 8.42%。

主要市场统计数据
基准年 2024 19.2亿美元
预计年份：2025年 20.8亿美元
预测年份：2032年 36.7亿美元
复合年增长率 (%) 8.42%

这是一份简洁且权威的报告，阐述了正在重新定义犬类关节炎管理和相关人员优先事项的临床、商业和看护者发展趋势。

犬类关节炎已从单纯的临床问题演变为一项多方面的挑战，需要临床医生、产品开发人员、支付者和看护者共同合作应对。儘管疼痛管理和关节保护等长期存在的临床难题依然是重中之重，但介入措施的选择和实施环境已发生显着变化。兽医专业人员需要在满足饲主对生活品质的期望、能够改变疾病进程的新型治疗方法以及具备数位化素养、要求透明证据和便捷治疗途径的饲主群体之间寻求平衡。因此，成功的策略必须将临床疗效与支持实际治疗依从性、可负担性和慢性病管理的模式结合。

科学、消费行为和医疗服务领域发生的引人注目的变革性变化正在重新定义犬类关节炎的治疗管道和商业模式。

由于科学创新、饲主期望的改变以及护理模式的演进，犬类关节炎的治疗格局正在改变。在科学方面，针对单株抗体和改良型缓解疾病药物的出现，使得人们更加关注针对潜在病理的干预措施，而不仅仅是缓解症状。这些进展正在开闢新的临床途径，并促使兽医从业人员重新评估传统的治疗流程。此外，从远端医疗咨询到穿戴式活动监测器等技术的整合，使得对运动功能和治疗反应的持续评估成为可能，从而进一步实现个人化护理，并有助于指导长期治疗决策。

基于证据的分析，探讨2025年关税调整如何重塑犬类关节炎治疗管道的采购、定价和供应韧性。

2025年关税的累积影响正波及犬类关节炎价值链中的采购、定价与策略采购决策。某些药品成分、进口成品药和专用復健设备的关税上调，导致到岸成本增加，并为采购计画带来波动。为此，製造商和经销商正在使其供应链多元化，并评估各种替代方案，包括近岸外包、供应商整合以及在临床可接受的情况下使用国内采购的组件。虽然这些调整有助于降低风险，但也需要重新分配资金，并调整与经销商和兽医合作伙伴的合约条款。

透过整合治疗方法、药物类别、给药途径、分销管道、最终用户和公司定位等因素，进行全面的細項分析，从而确定采用管道。

细分市场的洞察揭示了治疗方案、药理学、给药途径、分销、终端用户和企业策略如何相互交织，共同塑造护理模式。根据治疗类型，市场可分为辅助疗法、非药物疗法和药物疗法。辅助疗法包括营养补充剂，而补充剂类别可进一步细分为软骨素、葡萄糖胺和ω脂肪酸。非药物疗法包括针灸、雷射疗法和物理疗法，其中物理疗法可分为水疗和物理疗法。另一方面，药物疗法包括缓解疾病缓解疾病药物（DMDs），例如透明质酸和多硫酸Glico；单株抗体，例如贝地维托单抗；以及非类固醇消炎剂），例如卡洛芬、德拉考昔和美洛昔康。将药物按类别分为骨关节炎治疗药物、单株抗体和非类固醇消炎剂，重申了临床治疗向缓解疾病和靶向生技药品的转变，其中透明质酸和多硫酸Glico是前一类药物的基石，贝地贝单抗为抗体疗法提供了明确的参考点，而抗发炎的非类固醇则是一种常用的美洛昔康抗发炎药物。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 犬类干细胞疗法需求不断增长，为关节再生修復提供了可能。
  • 将穿戴式犬类活动追踪器整合到关节炎管理中，以改善关节炎管理。
  • 扩大老年犬隻的订阅式关节补充品配送服务
  • 再生医学中富血小板血浆通讯协定在缓解犬骨关节炎的进展
  • 监管政策调整旨在加速犬类关节炎新疗法的核准流程
  • 提供远距兽医关节炎咨询和监测的远距远端照护平台发展迅速
  • 实施个人化营养计划，纳入富含Omega-3的食物，以支持关节健康。
  • 透过製药公司与兽医技术Start-Ups之间的策略合作，创新治疗方案
  • 消费者对含有新型生物活性化合物的植物来源关节补充剂兴趣激增
  • 亚太市场扩张的驱动力来自宠物饲养量的增加和兽医基础设施的扩建。

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 犬类关节炎治疗市场：依治疗方法

  • 辅助疗法
    • 营养补充品
    • 补充
      • 软骨素
      • 葡萄糖胺
      • 欧米伽脂肪酸
  • 非药物疗法
    • 针刺
    • 雷射疗法
    • 物理治疗
      • 水处理方法
      • 物理治疗
  • 药物治疗
    • 缓解疾病抗风湿药物
      • 玻尿酸
      • 多硫酸Glico聚醣
    • 单株抗体
      • 贝丁维托马
    • 非类固醇消炎剂
      • 卡洛芬
      • 德拉考昔
      • 美洛昔康

9. 犬类关节炎治疗药物市场

  • 骨关节炎治疗
    • 玻尿酸
    • 多硫酸Glico聚醣
  • 单株抗体
    • 贝丁维托马
  • 非类固醇消炎剂
    • 卡洛芬
    • 德拉考昔
    • 美洛昔康

第十章 犬类关节炎治疗市场（依给药途径划分）

  • 注射
    • 皮下注射
  • 口服
    • 片剂和胶囊
  • 外用药物
    • 凝胶

第十一章 犬类关节炎治疗市场（依通路划分）

  • 网路药房
    • 综合电子商务平台
    • 兽医的电子商务平台
  • 宠物专卖店
  • 零售药房
  • 兽医院药房

第十二章 犬类关节炎治疗市场（依最终使用者划分）

  • 专业宠物诊所
    • 復健中心
  • 动物诊所
    • 综合诊所
    • 整形外科诊所
  • 兽医诊所
    • 综合兽医院
    • 小动物医院

第十三章 犬类关节炎治疗市场：依公司划分

  • Dechra
  • Elanco
  • Zoetis

第十四章 犬类关节炎治疗市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 犬类关节炎治疗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国犬类关节炎治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Zoetis Inc.
    • Elanco Animal Health Incorporated
    • Merck & Co., Inc.
    • Dechra Pharmaceuticals PLC
    • Vetoquinol SA
    • Virbac SA
    • Boehringer Ingelheim International GmbH
    • Nutramax Laboratories, Inc.
    • Colgate-Palmolive Company
    • Nestle SA
Product Code: MRR-1A1A064C0106

The Canine Arthritis Market is projected to grow by USD 3.67 billion at a CAGR of 8.42% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.92 billion
Estimated Year [2025] USD 2.08 billion
Forecast Year [2032] USD 3.67 billion
CAGR (%) 8.42%

A concise and authoritative introduction to the evolving clinical, commercial, and caregiver dynamics that are redefining canine arthritis management and stakeholder priorities

Canine arthritis has evolved from a narrowly clinical concern into a multifaceted challenge that demands integrated responses from clinicians, product developers, payors, and caregivers. Longstanding clinical imperatives such as pain control and joint preservation remain central, yet the context in which interventions are selected and delivered has shifted dramatically. Veterinary practitioners are balancing owner expectations for quality of life, emerging therapeutic classes that alter disease trajectory, and an increasingly digital-savvy pet owner population that seeks transparent evidence and convenient access to treatments. As a result, successful strategies must bridge clinical efficacy with real-world adherence, affordability, and service delivery models that support chronic disease management.

In parallel, research and innovation are broadening the therapeutic toolkit available to veterinarians and owners. Novel biologics and targeted therapies are being integrated alongside established pharmacological agents and a resurgent interest in nonpharmacological modalities. This plurality of options elevates the importance of comparative clinical evidence, practical guidelines for multimodal care, and communication strategies that synthesize risk-benefit profiles for diverse patient cohorts. Consequently, stakeholders must approach canine arthritis not only as a medical condition but as an ecosystem that includes preventive care, rehabilitation, nutritional strategies, and digital monitoring.

Compelling transformative shifts in science, consumer behavior, and care delivery that are redefining treatment pathways and commercial models for canine arthritis

The landscape of canine arthritis is undergoing transformative shifts driven by scientific innovation, changing client expectations, and evolving care delivery models. On the scientific front, the emergence of targeted monoclonal antibodies and refined disease modifying agents has redirected attention toward interventions that address underlying pathology rather than only symptomatic relief. These advances are catalyzing new clinical pathways and prompting veterinary clinicians to reassess long-standing treatment algorithms. Furthermore, technological integration-ranging from telehealth consultations to wearable activity monitors-enables continuous assessment of mobility and treatment response, thereby improving personalization of care and informing long-term therapeutic decisions.

Concurrently, client expectations are reshaping market dynamics. Pet owners increasingly evaluate treatment options through the lens of long-term outcomes, safety profiles, and convenience. This shift elevates the role of complementary therapies and rehabilitation services as acceptable components of multimodal regimens. Finally, commercial and regulatory pressures are prompting manufacturers and distributors to rethink supply chain resilience and pricing strategies. As stakeholders adapt, the industry is moving toward integrated care models that combine pharmacological therapies, nonpharmacological interventions, and owner-centered support to optimize outcomes across diverse canine populations.

An evidence-oriented analysis of how United States tariff adjustments in twenty twenty five are reshaping procurement, pricing, and supply resilience across canine arthritis care pathways

The cumulative impact of tariffs implemented in the United States in twenty twenty five reverberates across procurement, pricing, and strategic sourcing decisions within the canine arthritis value chain. Tariff escalations on select pharmaceutical ingredients, finished imported formulations, and specialized rehabilitation equipment have increased landed costs and introduced volatility in procurement planning. In response, manufacturers and distributors have intensified scrutiny of supply chain diversification, evaluating alternatives such as nearshoring, vendor consolidation, and substitution with domestically sourced components where clinically acceptable. These adaptations, while mitigating exposure, have required capital reallocation and adjustments to contractual terms with distributors and veterinary partners.

Clinicians and practice managers have observed indirect consequences in the clinic, including tighter inventory management and incremental cost pass-through for certain imported therapeutics or advanced rehabilitation devices. At the same time, the tariff environment has accentuated the competitive advantage of companies with vertically integrated production or established domestic manufacturing footprints, as these players can buffer price increases and maintain supply continuity. Importantly, the policy-induced cost pressures have also stimulated innovation in product formulation and delivery, with stakeholders exploring low-cost manufacturing techniques, reformulation to reduce reliance on affected inputs, and extended-duration therapeutics that reduce frequency of procurement and improve adherence.

Comprehensive segmentation insights integrating treatment modalities, drug classes, administration routes, distribution channels, end users, and company positioning to reveal adoption pathways

Segment-specific insights reveal how treatment choices, pharmacology, administration routes, distribution, end users, and company strategies intersect to shape care patterns. Based on treatment type, the market divides into complementary therapies, nonpharmacological therapies, and pharmacological therapies, where complementary therapies encompass nutraceuticals and supplements and the supplements category further includes chondroitin, glucosamine, and omega fatty acids; nonpharmacological therapies encompass acupuncture, laser therapy, and physical therapy with physical therapy branching into hydrotherapy and physiotherapy, while pharmacological therapies include disease modifying agents, monoclonal antibodies, and nonsteroidal anti inflammatory drugs, the disease modifying agents further characterized by hyaluronic acid and polysulfated glycosaminoglycan, monoclonal antibodies represented by bedinvetmab, and nonsteroidal anti inflammatory drugs exemplified by carprofen, deracoxib, and meloxicam. Based on drug class, the breakdown into disease modifying osteoarthritic agents, monoclonal antibodies, and nonsteroidal anti inflammatory drugs reiterates the clinical pivot toward disease modification and targeted biologics, with hyaluronic acid and polysulfated glycosaminoglycan anchoring the former category and bedinvetmab providing a clear reference point for antibody therapies while carprofen, deracoxib, and meloxicam represent commonly used NSAIDs.

Based on route of administration, injectable, oral, and topical formats frame clinical decision making, with injectable options often delivered subcutaneously and oral therapies typically administered in tablet or capsule form while topical preparations are commonly available in gel formulations. Based on distribution channel, online pharmacies, pet specialty stores, retail pharmacies, and veterinary hospital pharmacies define access pathways, with online channels segmented between general e commerce platforms and specialized veterinary e commerce platforms that influence adherence and price transparency. Based on end user, specialty pet clinics, veterinary clinics, and veterinary hospitals reflect where care is delivered; specialty pet clinics frequently include rehabilitation centers, veterinary clinics can be divided into general practice and orthopedic clinics, and veterinary hospitals range from multispecialty facilities to small animal hospitals. Based on company, market activity concentrates among established players such as Dechra, Elanco, and Zoetis, each shaping product development, distribution strategies, and clinical education in distinct ways. Taken together, these segmentation frames illuminate where clinical innovation, commercial investment, and practical adoption are converging and where gaps remain for targeted evidence generation and service optimization.

Key regional dynamics and market entry considerations across the Americas, Europe Middle East and Africa, and Asia Pacific that influence adoption, access, and commercialization strategies

Regional dynamics materially influence research priorities, regulatory pathways, and commercial approaches across the Americas, Europe Middle East and Africa, and Asia Pacific, each presenting distinct epidemiological profiles and care delivery ecosystems. In the Americas, high pet ownership rates and advanced veterinary practice infrastructure favor rapid uptake of novel therapeutics and integrated care models, while direct-to-consumer digital channels and robust specialty clinic networks support adoption of multimodal regimens and rehabilitation services. Conversely, Europe Middle East and Africa exhibit heterogeneous regulatory frameworks and variable access to high-cost biologics, which creates differentiated market corridors where domestically produced formulations and cost-effective complementary therapies often find traction.

In the Asia Pacific region, rapid modernization of veterinary services, growing pet-owning middle classes, and expanding online retail ecosystems are accelerating demand for both established pharmaceuticals and innovative modalities, yet distribution complexity and regulatory variance require localized commercialization strategies. Across regions, differences in veterinary workforce capacity, reimbursement norms, and owner willingness to invest in chronic disease management drive divergent adoption curves for advanced therapeutics and supportive services. As a result, regional strategies must be calibrated to local regulatory realities, channel structures, and owner expectations to unlock sustainable growth and meaningful clinical impact.

Key company profiles and strategic positioning that explain how scale, specialization, and R&D focus drive competitive advantage in the canine arthritis ecosystem

Company-level positioning demonstrates how scale, pipeline composition, and commercial capabilities determine competitive advantage in canine arthritis. Dechra is recognized for its focus on specialty veterinary pharmaceuticals and customer-centric distribution strategies that reinforce relationships with clinical decision makers. Elanco leverages a broad portfolio and global reach to support integrated product rollouts and collaborative research partnerships with academic and clinical institutions. Zoetis combines deep R&D capabilities with extensive field sales forces and clinician education programs that drive clinical uptake and post-launch evidence generation. Together, these companies exemplify different strategic archetypes: specialized specialty-focused execution, diversified portfolio leverage, and scale-driven clinical influence.

Beyond these leading players, a range of smaller innovators and contract manufacturers contribute to category evolution by introducing novel formulations, digital monitoring tools, and localized manufacturing partnerships. Strategic collaborations among incumbents and niche technology providers are increasingly important for translating biologic advances into scalable clinical solutions. For industry stakeholders, identifying the role each company plays in the distribution ecosystem and clinical education landscape informs partnership strategies, competitive benchmarking, and tactical investment decisions.

Practical and prioritized recommendations for industry leaders to align clinical evidence, integrated care pathways, and supply chain resilience for sustained competitive advantage

Actionable recommendations for leaders focus on aligning clinical value, commercial feasibility, and operational resilience to capture long term opportunity. First, prioritize evidence generation that addresses comparative effectiveness, long term safety, and real world outcomes for multimodal regimens, ensuring that clinical trials and postmarket studies are designed to produce practice-relevant endpoints. Second, invest in integrated care pathways that combine pharmacological, nonpharmacological, and supportive services, and pair these programs with digital tools that simplify owner engagement and adherence monitoring. Third, fortify supply chain resilience by diversifying sourcing, evaluating nearshoring options, and developing contingency plans for imported inputs to mitigate tariff and import volatility.

In addition, cultivate deep clinician partnerships through continuing education, practical toolkits for multimodal therapy implementation, and co developed case registries that accelerate learning. Align commercial strategies with regional realities by tailoring pricing, channel mix, and regulatory engagement to local market dynamics. Finally, assess strategic collaborations with smaller innovators and service providers to accelerate time to market for differentiated offerings while leveraging incumbents' distribution and clinician education capabilities. Implementing these recommendations will strengthen competitive positioning and improve care outcomes across diverse clinical and commercial contexts.

A transparent research methodology combining primary clinician interviews, secondary clinical and regulatory review, and analytical triangulation to support actionable insights

The research underpinning this executive summary combines qualitative and quantitative approaches to ensure robust, multiperspective analysis. Primary research included structured interviews with veterinary clinicians, practice managers, and industry executives to capture clinical practice patterns, adoption drivers, and commercial priorities. Secondary research reviewed peer reviewed clinical literature, regulatory guidance, public company disclosures, and product monographs to corroborate findings and contextualize technological trajectories. Comparative analyses were performed to map therapeutic mechanisms, administration routes, and distribution channel economics against observed adoption trends.

Analytical methods encompassed thematic synthesis of interview data, cross validation of product and company claims with regulatory filings and clinical trial registries, and scenario analysis to evaluate the operational impacts of supply chain and policy shifts. Throughout the process, emphasis was placed on triangulation between clinician experience, commercial intelligence, and documented clinical evidence to reduce bias and strengthen practical relevance. The methodology supports actionable insights by focusing on implementation barriers, evidence gaps, and strategic levers that stakeholders can operationalize within their organizations.

A forward-looking conclusion synthesizing clinical advances, operational challenges, and strategic imperatives that must be reconciled to improve canine arthritis outcomes

In conclusion, canine arthritis represents a dynamic area where scientific advances, client expectations, and commercial realities intersect to create both complexity and opportunity. The maturation of disease modifying agents and targeted biologics offers the potential to shift treatment paradigms toward longer term joint health, while nonpharmacological and complementary therapies are increasingly recognized as essential components of multimodal care. Regional and policy variables, such as tariff changes and distribution channel evolution, introduce operational challenges that demand proactive supply chain and pricing strategies. Success in this environment will require stakeholders to invest in rigorous evidence generation, clinician engagement, and pragmatic commercialization models that prioritize real world outcomes and owner adherence.

Moving forward, organizations that combine clinical credibility with operational agility and collaborative partnerships will be best positioned to deliver meaningful improvements in canine mobility and quality of life. By aligning research priorities with practical implementation pathways and regional market nuances, stakeholders can convert scientific promise into scalable clinical and commercial outcomes that address both current needs and future opportunities.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising demand for canine stem cell therapies offering regenerative joint repair
  • 5.2. Integration of wearable canine activity monitors to enhance arthritis management outcomes
  • 5.3. Expansion of subscription based joint supplement delivery services targeting senior dogs
  • 5.4. Advancements in canine regenerative platelet rich plasma protocols for osteoarthritis relief
  • 5.5. Regulatory updates accelerating approval pathways for novel canine arthritis therapeutics
  • 5.6. Growth of telemedicine platforms providing remote veterinary arthritis consultations and monitoring
  • 5.7. Adoption of personalized nutrition plans incorporating omega 3 enriched diets for joint support
  • 5.8. Strategic partnerships between pharmaceutical companies and veterinary tech startups to innovate treatment options
  • 5.9. Surge in consumer interest for plant based joint supplements formulated with novel bioactive compounds
  • 5.10. Market expansion in Asia Pacific driven by increasing pet ownership and growing veterinary infrastructure

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Canine Arthritis Market, by Treatment Type

  • 8.1. Complementary Therapies
    • 8.1.1. Nutraceuticals
    • 8.1.2. Supplements
      • 8.1.2.1. Chondroitin
      • 8.1.2.2. Glucosamine
      • 8.1.2.3. Omega Fatty Acids
  • 8.2. Non Pharmacological Therapies
    • 8.2.1. Acupuncture
    • 8.2.2. Laser Therapy
    • 8.2.3. Physical Therapy
      • 8.2.3.1. Hydrotherapy
      • 8.2.3.2. Physiotherapy
  • 8.3. Pharmacological Therapies
    • 8.3.1. Disease Modifying Agents
      • 8.3.1.1. Hyaluronic Acid
      • 8.3.1.2. Polysulfated Glycosaminoglycan
    • 8.3.2. Monoclonal Antibodies
      • 8.3.2.1. Bedinvetmab
    • 8.3.3. Non Steroidal Anti Inflammatory Drugs
      • 8.3.3.1. Carprofen
      • 8.3.3.2. Deracoxib
      • 8.3.3.3. Meloxicam

9. Canine Arthritis Market, by Drug Class

  • 9.1. Disease Modifying Osteoarthritic Agents
    • 9.1.1. Hyaluronic Acid
    • 9.1.2. Polysulfated Glycosaminoglycan
  • 9.2. Monoclonal Antibodies
    • 9.2.1. Bedinvetmab
  • 9.3. Non Steroidal Anti Inflammatory Drugs
    • 9.3.1. Carprofen
    • 9.3.2. Deracoxib
    • 9.3.3. Meloxicam

10. Canine Arthritis Market, by Route Of Administration

  • 10.1. Injectable
    • 10.1.1. Subcutaneous
  • 10.2. Oral
    • 10.2.1. Tablet Capsule
  • 10.3. Topical
    • 10.3.1. Gel

11. Canine Arthritis Market, by Distribution Channel

  • 11.1. Online Pharmacies
    • 11.1.1. General E Commerce Platforms
    • 11.1.2. Vet E Commerce Platforms
  • 11.2. Pet Specialty Stores
  • 11.3. Retail Pharmacies
  • 11.4. Veterinary Hospital Pharmacies

12. Canine Arthritis Market, by End User

  • 12.1. Specialty Pet Clinics
    • 12.1.1. Rehabilitation Centers
  • 12.2. Veterinary Clinics
    • 12.2.1. General Practice Clinics
    • 12.2.2. Orthopedic Clinics
  • 12.3. Veterinary Hospitals
    • 12.3.1. Multispecialty Hospitals
    • 12.3.2. Small Animal Hospitals

13. Canine Arthritis Market, by Company

  • 13.1. Dechra
  • 13.2. Elanco
  • 13.3. Zoetis

14. Canine Arthritis Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Canine Arthritis Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Canine Arthritis Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Zoetis Inc.
    • 17.3.2. Elanco Animal Health Incorporated
    • 17.3.3. Merck & Co., Inc.
    • 17.3.4. Dechra Pharmaceuticals PLC
    • 17.3.5. Vetoquinol SA
    • 17.3.6. Virbac SA
    • 17.3.7. Boehringer Ingelheim International GmbH
    • 17.3.8. Nutramax Laboratories, Inc.
    • 17.3.9. Colgate-Palmolive Company
    • 17.3.10. Nestle S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANINE ARTHRITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY COMPANY, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY COMPANY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS CANINE ARTHRITIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANINE ARTHRITIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. CANINE ARTHRITIS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. CANINE ARTHRITIS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CANINE ARTHRITIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CANINE ARTHRITIS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CANINE ARTHRITIS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NUTRACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NUTRACEUTICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NUTRACEUTICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NUTRACEUTICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NUTRACEUTICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NUTRACEUTICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SUPPLEMENTS, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SUPPLEMENTS, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CHONDROITIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CHONDROITIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CHONDROITIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CHONDROITIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CHONDROITIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CHONDROITIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GLUCOSAMINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GLUCOSAMINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GLUCOSAMINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GLUCOSAMINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GLUCOSAMINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GLUCOSAMINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY OMEGA FATTY ACIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY OMEGA FATTY ACIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY OMEGA FATTY ACIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY OMEGA FATTY ACIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY OMEGA FATTY ACIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY OMEGA FATTY ACIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON PHARMACOLOGICAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON PHARMACOLOGICAL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON PHARMACOLOGICAL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON PHARMACOLOGICAL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON PHARMACOLOGICAL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON PHARMACOLOGICAL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON PHARMACOLOGICAL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ACUPUNCTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ACUPUNCTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ACUPUNCTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ACUPUNCTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ACUPUNCTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ACUPUNCTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY LASER THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY LASER THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY LASER THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY LASER THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY LASER THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY LASER THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYDROTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYDROTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYDROTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYDROTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYDROTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYDROTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYALURONIC ACID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYALURONIC ACID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYALURONIC ACID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYALURONIC ACID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYALURONIC ACID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYALURONIC ACID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY POLYSULFATED GLYCOSAMINOGLYCAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY POLYSULFATED GLYCOSAMINOGLYCAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY POLYSULFATED GLYCOSAMINOGLYCAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY POLYSULFATED GLYCOSAMINOGLYCAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY POLYSULFATED GLYCOSAMINOGLYCAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY POLYSULFATED GLYCOSAMINOGLYCAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY BEDINVETMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY BEDINVETMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY BEDINVETMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY BEDINVETMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY BEDINVETMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY BEDINVETMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CARPROFEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CARPROFEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CARPROFEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CARPROFEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CARPROFEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CARPROFEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DERACOXIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DERACOXIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DERACOXIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DERACOXIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DERACOXIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DERACOXIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MELOXICAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MELOXICAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MELOXICAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MELOXICAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MELOXICAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MELOXICAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING OSTEOARTHRITIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING OSTEOARTHRITIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING OSTEOARTHRITIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING OSTEOARTHRITIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING OSTEOARTHRITIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING OSTEOARTHRITIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING OSTEOARTHRITIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE MODIFYING OSTEOARTHRITIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYALURONIC ACID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYALURONIC ACID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYALURONIC ACID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYALURONIC ACID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYALURONIC ACID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYALURONIC ACID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY POLYSULFATED GLYCOSAMINOGLYCAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY POLYSULFATED GLYCOSAMINOGLYCAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY POLYSULFATED GLYCOSAMINOGLYCAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY POLYSULFATED GLYCOSAMINOGLYCAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY POLYSULFATED GLYCOSAMINOGLYCAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY POLYSULFATED GLYCOSAMINOGLYCAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY BEDINVETMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY BEDINVETMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY BEDINVETMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY BEDINVETMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY BEDINVETMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY BEDINVETMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON STEROIDAL ANTI INFLAMMATORY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CARPROFEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CARPROFEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CARPROFEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CARPROFEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CARPROFEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY CARPROFEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DERACOXIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DERACOXIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DERACOXIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DERACOXIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DERACOXIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DERACOXIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MELOXICAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MELOXICAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MELOXICAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MELOXICAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MELOXICAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY MELOXICAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TABLET CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TABLET CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TABLET CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TABLET CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TABLET CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TABLET CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GENERAL E COMMERCE PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GENERAL E COMMERCE PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GENERAL E COMMERCE PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GENERAL E COMMERCE PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GENERAL E COMMERCE PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY GENERAL E COMMERCE PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY VET E COMMERCE PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY VET E COMMERCE PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY VET E COMMERCE PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY VET E COMMERCE PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY VET E COMMERCE PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY VET E COMMERCE PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PET SPECIALTY STORES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PET SPECIALTY STORES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PET SPECIALTY STORES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PET SPECIALTY STORES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PET SPECIALTY STORES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PET SPECIALTY STORES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY VETERINARY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY VETERINARY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY VETERINARY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY VETERINARY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY VETERINARY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY VETERINARY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SPECIALTY PET CLINICS, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SPECIALTY PET CLINICS, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SPECIALTY PET CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SPECIALTY PET CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SPECIALTY PET CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SPECIALTY PET CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SPECIALTY PET CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SPECIALTY PET CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 312. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 313. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY REHABILITATION CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 314. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY REHABILITATION CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 315. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY REHABILITATION CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 316. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY REHABILITATION CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 317. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY VETERINARY CLINICS, 2018-2024 (USD MILLION)

TABLE 318.